Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Dermata Therapeutics, Inc. (DRMA)

0.7750 -0.0552 (-6.65%)
At close: October 30 at 4:00:01 PM EDT
0.7899 +0.0149 (+1.92%)
After hours: October 30 at 7:59:47 PM EDT
Chart Range Bar
Loading chart for DRMA
  • Previous Close 0.8302
  • Open 0.7990
  • Bid 0.8208 x 200
  • Ask 0.8745 x 100
  • Day's Range 0.7637 - 0.8290
  • 52 Week Range 0.6030 - 4.6600
  • Volume 61,673
  • Avg. Volume 3,437,337
  • Market Cap (intraday) 3.84M
  • Beta (5Y Monthly) 0.66
  • PE Ratio (TTM) --
  • EPS (TTM) -4.3900
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 4.00

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

www.dermatarx.com

9

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

DRMA
66.59%
S&P 500 (^GSPC)
10.73%

1-Year Return

DRMA
77.41%
S&P 500 (^GSPC)
11.11%

3-Year Return

DRMA
99.11%
S&P 500 (^GSPC)
81.91%

5-Year Return

DRMA
99.99%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -2.97M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-2M
-1M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

4.00
4.00 Average
0.7750 Current
4.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/21/2025
Analyst Maxim Group
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 30 -> 10

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -89.88%

  • Return on Equity (ttm)

    -183.89%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -8.37M

  • Diluted EPS (ttm)

    -4.3900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.41M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -5.11M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: